(Q38167181)

30 August 2017

title

Reassessing the two-year rodent carcinogenicity bioassay: a review of the applicability to human risk and current perspectives (English)

1 reference

30 August 2017

Palma Ann Marone

1

1 reference

30 August 2017

William C Hall

series ordinal

2

1 reference

30 August 2017

A Wallace Hayes

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

25 November 2013

1 reference

Regulatory Toxicology and Pharmacology

30 August 2017

published in

1 reference

30 August 2017

volume

68

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

108-118

1 reference

International prevalidation studies of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A critical appraisal of the value of the mouse cancer bioassay in safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Neoplastic lesions of questionable significance to humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

An Improved Bacterial Test System for the Detection and Classification of Mutagens and Carcinogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Expectations for transgenic rodent cancer bioassay models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The expanding role of predictive toxicology: an update on the (Q)SAR models for mutagens and carcinogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Alternative strategies for carcinogenicity assessment: an efficient and simplified approach based on in vitro mutagenicity and cell transformation assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Exploring In Vitro/In Vivo Correlation: Lessons Learned from Analyzing Phase I Results of the US EPA's ToxCast Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

IPCS framework for analyzing the relevance of a cancer mode of action for humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Chemogenomics: an emerging strategy for rapid target and drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The National Toxicology Program rodent bioassay: designs, interpretations, and scientific contributions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Human carcinogenic risk evaluation, Part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

7 January 2021

Mouse Models of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Factors in the evaluation of 200 national cancer institute carcinogen bioassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The science and practice of carcinogen identification and evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Alternative models for carcinogenicity testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The international symposium on regulatory testing and animal welfare: recommendations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Best practices guideline: toxicologic histopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Use of QSARs in international decision-making frameworks to predict health effects of chemical substances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Chemical carcinogenesis - mode of action to inform quantitative human risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The ToxCast program for prioritizing toxicity testing of environmental chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Incorporating Biological, Chemical, and Toxicological Knowledge Into Predictive Models of Toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Review of pathology data for regulatory purposes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Short- and intermediate-term carcinogenicity testing--a review. Part 2: available experimental models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Successful drug development despite adverse preclinical findings part 2: examples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Guidance on conducting repeated-dose 90-day oral toxicity study in rodents on whole food/feed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Concordance between rats and mice in bioassays for carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The use of transgenic animals in cancer testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Experimental design of bioassays for screening and low dose extrapolation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Target organs in chronic bioassays of 533 chemical carcinogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Regulatory forum opinion piece: long-term animal bioassays: is the end near?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Mode of action frameworks: a critical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

An expert consortium review of the EC-commissioned report "alternative (Non-Animal) methods for cosmetics testing: current status and future prospects - 2010".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Evaluation of false positive and false negative outcomes in NTP long-term rodent carcinogenicity studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A rapid in vivo test for chromosomal damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Reprogramming metastatic tumour cells with embryonic microenvironments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

In vitro sensitivity assays in cancer: a review, analysis, and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The limits of two-year bioassay exposure regimens for identifying chemical carcinogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The history of tumor virology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Cancer risk assessment approaches at the FDA/CDER: Is the era of the 2-year bioassay drawing to a close?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Use of transgenic mice in carcinogenicity hazard assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Best practices for use of historical control data of proliferative rodent lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

PPARalpha agonist-induced rodent tumors: modes of action and human relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Detailed review of transgenic rodent mutation assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Pathology and tissue sampling protocols for rodent carcinogenicity studies: time for revision

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Critical review of the role of HTS in drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Longer Rodent Bioassay Fails to Address 2-Year Bioassay’s Flaws

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

A framework for human relevance analysis of information on carcinogenic modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Conflicting views on chemical carcinogenesis arising from the design and evaluation of rodent carcinogenicity studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The Tg rasH2 mouse in cancer hazard identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Improving carcinogenicity assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Case study: weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

How genetically engineered mouse tumor models provide insights into human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Optimal design of the chronic animal bioassay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The role of transgenic mouse models in carcinogen identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Laboratory animal tests and human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

An evaluation of chronic 6- and 12-month rat toxicology studies as predictors of 2-year tumor outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

7 January 2021

The micronucleus test

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

PPAR gamma and human metabolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Dose-dependent transitions in mechanisms of toxicity: case studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The value and significance of life span and scheduled termination data in long-term toxicity and carcinogenesis studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Application of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Improving the human hazard characterization of chemicals: a Tox21 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Human carcinogens so far identified

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Alternatives models in carcinogenicity testing--a European perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Global government applications of analogues, SARs and QSARs to predict aquatic toxicity, chemical or physical properties, environmental fate parameters and health effects of organic chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The roles of the toxicologic pathologist in cancer research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The decision-point approach for systematic carcinogen testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Carcinogen testing: current problems and new approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Application of mode-of-action considerations in human cancer risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Systematic carcinogen testing through the decision point approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Application of a cellular test battery in the decision point approach to carcinogen identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

The Role of Qsar Methodology in the Regulatory Assessment of Chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Best practices for clinical pathology testing in carcinogenicity studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini Foundation and the National Toxicology Program: in tribute to Cesare Maltoni and David Rall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2013.11.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YRTPH.2013.11.011

1 reference

30 August 2017

1 reference